Company Product Description Indication Status
Abbvie Inc., of North Chicago Botox (onabotulinumtoxinA) Acts on motor neurons to reduce muscle activity Pediatric patients with neurogenic detrusor overactivity FDA accepted sBLA 
Altimmune Inc., of Gaithersburg, Md. Heptcell Peptide-based immunotherapeutic Chronic hepatitis B FDA cleared IND for phase II trial
Basilea Pharmaceutical Ltd., of Basel, Switzerland Cresemba (isavuconazole) Antifungal Invasive aspergillosis; mucormycosis in adult patients for whom amphotericin B is inappropriate Russian Federation granted marketing authorization
Bio-Thera Solutions Ltd., of Guangzhou, China BAT-1706 Biosimilar to Avastin (bevacizumab, Roche Holding AG) Advanced, metastatic or relapsed non-small-cell lung cancer and metastatic colorectal cancer China National Medical Products Administration accepted the BLA
Deciphera Pharmaceuticals Inc., of Waltham, Mass. Qinlock (ripretinib) Switch-control tyrosine kinase inhibitor Advanced gastrointestinal stromal tumor in patients who have received prior treatment  Health Canada authorized product for sale
Merck & Co. Inc., of Kenilworth, N.J. Keytruda (pembrolizumab) Anti-PD-1 therapy Metastatic squamous non-small-cell lung cancer Approved by the National Medical Products Administration (NMPA) in China for use in combination with carboplatin and paclitaxel for the first-line treatment
Nabriva Therapeutics plc, of Dublin Contepo (fosfomycin)  Antibiotic Complicated urinary tract infections Received complete response letter from FDA
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Sanofi SA, of Paris Dupixent (dupilumab) Fully human monoclonal antibody targeting IL-4 and IL-13 Atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis FDA approved a 300-mg single-dose prefilled pen
Resverlogix Corp., of Calgary, Alberta Apabetalone Targets bromodomain and extra terminal domain proteins Atherosclerosis FDA accepted BETonMACE2 clinical plan as a registration-enabling study 

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments